LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of standard of care including high intensity statins.
LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of…
LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of…
AbstractAims. We aimed to assess the role of multimodality imaging (MMI) in the diagnosis of marantic endocarditis (ME) associated with cancers and to describe
This randomized trial assesses the comparative effectiveness of direct oral anticoagulants vs low-molecular-weight heparin on rate of 6-month recurrence of venous thromboembolism (VTE) among patients…
AbstractBackground. Several aetiologies account for exercise intolerance, with cardiac sarcoidosis (CS) constituting a rare cause thereof. The pathogenesis of C
Your access to the latest cardiovascular news, science, tools and resources.
Heart failure is a complex clinical syndrome, whose signs and symptoms are caused by functional or structural impairment of ventricular filling or ejection of blood.…
Systemic hypertension remains a constant threat to global health due to its direct contribution to premature morbidity and excessive mortality.1 The risks assoc
A 55-year-old male with history of gastro-intestinal stromal tumour presents to the emergency department 7 days after undergoing distal partial gastrectomy, gas
The aim of this meta-analysis was to investigate the effects of concurrent, aerobic, and resistance exercises on markers of inflammation and vascular …
